JGC
GILD icon

J. Goldman & Co’s Gilead Sciences GILD Stock Holding History

J. Goldman & Co’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-40,000
Closed -$4.91M – 740
2025
Q4 		$4.91M Hold
40,000
– – 0.13% 199
2025
Q3 		$4.44M Buy
+40,000
New +$4.55M 0.11% 212
2025
Q2 		– Sell
-30,000
Closed -$3.36M – 528
2025
Q1 		$3.36M Buy
+30,000
New +$3.1M 0.08% 243
2024
Q1 		– Sell
-27,000
Closed -$2.19M – 445
2023
Q4 		$2.19M Sell
27,000
-8,000
-23% -$623K 0.09% 179
2023
Q3 		$2.62M Buy
+35,000
New +$2.69M 0.09% 185
2022
Q4 		– Sell
-95,000
Closed -$5.86M – 418
2022
Q3 		$5.86M Buy
+95,000
New +$5.99M 0.28% 106

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

J. Goldman & Co's GILD Position: Q2 2026 in Review

J. Goldman & Co sold out of Gilead Sciences (GILD) in Q2 2026, closing a stake of 74,912 shares — an estimated $10.4M sold.

J. Goldman & Co first reported a position in GILD in Q1 2017 and held it in 10 quarters. The position peaked at $20.9M in Q3 2025. 2,293 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • J. Goldman & Co reported no remaining Gilead Sciences position as of Q2 2026 after selling out during the quarter.
  • J. Goldman & Co sold 74,912 Gilead Sciences shares in Q2 2026, an estimated $10.4M.
  • J. Goldman & Co first reported a position in Gilead Sciences in Q1 2017 and held it in 10 quarters.
  • J. Goldman & Co's Gilead Sciences position peaked at $20.9M in Q3 2025.
  • 2,293 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on J. Goldman & Co's 13F filing for Q2 2026, filed 14 Aug 2026.